A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
| Autor: | Julia Karbach, Elisabeth Stockert, Ivan Gout, Elke Jager, Alexander Knuth, Matthew J. Scanlan, Lloyd J. Old, Michael Arand, Yao-Tseng Chen |
|---|---|
| Přispěvatelé: | University of Zurich, Stockert, E |
| Rok vydání: | 1998 |
| Předmět: |
2403 Immunology
biology Immunology Autoantibody 10050 Institute of Pharmacology and Toxicology Cancer 610 Medicine & health medicine.disease 3. Good health 03 medical and health sciences 0302 clinical medicine Immune system Antigen 030220 oncology & carcinogenesis Blocking antibody 2723 Immunology and Allergy biology.protein medicine 570 Life sciences Immunology and Allergy Antibody NY-ESO-1 Melanoma-Specific Antigens 030215 immunology |
| Zdroj: | Journal of Experimental Medicine. 187:1349-1354 |
| ISSN: | 1540-9538 0022-1007 |
| DOI: | 10.1084/jem.187.8.1349 |
| Popis: | Evidence is growing for both humoral and cellular immune recognition of human tumor antigens. Antibodies with specificity for antigens initially recognized by cytotoxic T lymphocytes (CTLs), e.g., MAGE and tyrosinase, have been detected in melanoma patient sera, and CTLs with specificity for NY-ESO-1, a cancer-testis (CT) antigen initially identified by autologous antibody, have recently been identified. To establish a screening system for the humoral response to autoimmunogenic tumor antigens, an enzyme-linked immunosorbent assay (ELISA) was developed using recombinant NY-ESO-1, MAGE-1, MAGE-3, SSX2, Melan-A, and tyrosinase proteins. A survey of sera from 234 cancer patients showed antibodies to NY-ESO-1 in 19 patients, to MAGE-1 in 3, to MAGE-3 in 2, and to SSX2 in 1 patient. No reactivity to these antigens was found in sera from 70 normal individuals. The frequency of NY-ESO-1 antibody was 9.4% in melanoma patients and 12.5% in ovarian cancer patients. Comparison of tumor NY-ESO-1 phenotype and NY-ESO-1 antibody response in 62 stage IV melanoma patients showed that all patients with NY-ESO-1+ antibody had NY-ESO-1+ tumors, and no patients with NY-ESO-1− tumors had NY-ESO-1 antibody. As the proportion of melanomas expressing NY-ESO-1 is 20–40% and only patients with NY-ESO-1+ tumors have antibody, this would suggest that a high percentage of patients with NY-ESO-1+ tumors develop an antibody response to NY-ESO-1. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|